This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
An updated, final analysis from the phase III FLAURA study showed that compared with older EGFR inhibitors, the third-generation drug osimertinib was better tolerated and significantly improved overall survival among patients newly diagnosed with EGFR-mutant non–small cell lung cancer.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't.
Published OnlineFirst October 7, 2019
doi: 10.1158/2159-8290.CD-NB2019-120
Osimertinib Holds Its Own in NSCLC
Jump to section
Advertisement